[pubmed] Clinical characteristics and outcomes of thymoma associated myasthenia gravis
Posté : 15 mars 2021 11:00
Eur J Neurol. 2021 Mar 15. doi: 10.1111/ene.14820. Online ahead of print.
ABSTRACT
BACKGROUND: Prognosis of myasthenia gravis (MG) in patients with thymoma is not well established. Moreover, it is not clear whether thymoma recurrence or unresectable lesions entail a worse prognosis of MG.
METHODS: This multicenter study was based on data from a Spanish neurologist-driven MG registry. All patients were >18 years at onset and had anti-acetylcholine receptor antibodies. We compared the clinical data of thymomatous and non-thymomatous patients. Prognosis of patients with recurrent or non-resectable thymomas was assessed.
RESULTS: We included 964 patients from 15 hospitals: 148 (15.4%) had thymoma-associated MG. Median follow-up time was 4.6 years. At onset, thymoma-associated MG patients were younger (52.0 vs 60.4, p
Source: https://pubmed.ncbi.nlm.nih.gov/3372138 ... 5&v=2.14.3